

58. Vang R, Visvanathan K, Gross A, et al. Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma. *Int J Gynecol Pathol.* 2012;31(3):243-253.
59. Koc N, Ayas S, Arinkan SA. Comparison of the classical method and SEE-FIM protocol in detecting microscopic lesions in fallopian tubes with gynecological lesions. *J Pathol Transl Med.* 2018;52(1):21-27.
60. Steenbeek MP, van Bommel MHD, Bulten J, et al. Risk of peritoneal carcinomatosis after risk-reducing salpingo-oophorectomy: a systematic review and individual patient data meta-analysis. *J Clin Oncol.* 2022;40(17):1879-1891.
61. Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. *Lancet.* 2015;386(9990):249-257.
62. Onda T, Satoh T, Ogawa G, et al. Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial. *Eur J Cancer.* 2020;130:114-125.
63. Fagotti A, Ferrandina MG, Vizzielli G, et al. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). *Int J Gynecol Cancer.* 2020;30(11):1657-1664.
64. Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. *N Engl J Med.* 2010;363(10):943-953.
65. Fuso L, Ferrero A, Vietti E, et al. Development of a preoperative computed tomography score for the management of advanced epithelial ovarian cancer. *Int J Gynecol Cancer.* 2019;29(3):599-604.
66. Michielsen K, Dresen R, Vanslembrouck R, et al. Diagnostic value of whole body diffusion-weighted MRI compared to computed tomography for pre-operative assessment of patients suspected for ovarian cancer. *Eur J Cancer.* 2017;83:88-98.
67. Engbersen MP, van TSI, Lok C, et al. MRI with diffusion-weighted imaging to predict feasibility of complete cytoreduction with the peritoneal cancer index (PCI) in advanced stage ovarian cancer patients. *Eur J Radiol.* 2019;114:146-151.
68. Michielsen K, Vergote I, Op de Beeck K, et al. Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT. *Eur Radiol.* 2014;24(4):889-901.
69. Khiewvan B, Torigan DA, Emamzadehfard S, et al. An update on the role of PET/CT and PET/MRI in ovarian cancer. *Eur J Nucl Med Mol Imaging.* 2017;44(6):1079-1091.
70. Querleu D, Planchamp F, Chiva L, et al. European society of gynaecologic oncology quality indicators for advanced ovarian cancer surgery. *Int J Gynecol Cancer.* 2016;26(7):1354-1363.
71. Fotopoulou C, Concin N, Planchamp F, et al. Quality indicators for advanced ovarian cancer surgery from the European Society of Gynaecological Oncology (ESGO): 2020 update. *Int J Gynecol Cancer.* 2020;30(4):436-440.
72. Grabowski JP, Harter P, Heitz F, et al. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. *Gynecol Oncol.* 2016;140(3):457-462.
73. Harter P, Sehouli J, Lorusso D, et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. *N Engl J Med.* 2019;380(9):822-832.
74. Nasioudis D, Latif NA, Haggerty AF, et al. Outcomes of comprehensive lymphadenectomy for patients with advanced stage ovarian carcinoma and rare histologic sub-types. *Int J Gynecol Cancer.* 2021;31(8):1132-1136.
75. Acs M, Piso P, Prader S. Current status of metastatic cardiophrenic lymph nodes (CPLNs) in patients with ovarian cancer: a review. *Anticancer Res.* 2022;42(1):13-24.
76. Kengsakul M, Nieuwenhuijzen-de Boer GM, Bijleveld AHJ, et al. Survival in advanced-stage epithelial ovarian cancer patients with cardiophrenic lymphadenopathy who underwent cytoreductive surgery: a systematic review and meta-analysis. *Cancers (Basel).* 2021;13(19):5017.
77. van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. *N Engl J Med.* 2018;378(3):230-240.
78. Vergote I, Chiva L, du Bois A. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. *N Engl J Med.* 2018;378(14):1362-1363.
79. Koole SN, van Driel WJ, Sonke GS. Hyperthermic intraperitoneal chemotherapy for ovarian cancer: the heat is on. *Cancer.* 2019;125(suppl 24):4587-4593.
80. Vergote I, Harter P, Chiva L. Hyperthermic intraperitoneal chemotherapy does not improve survival in advanced ovarian cancer. *Cancer.* 2019;125(suppl 24):4594-4597.
81. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. *N Engl J Med.* 2011;365(26):2473-2483.
82. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. *N Engl J Med.* 2011;365(26):2484-2496.
83. Grisham RN, Iyer G, Sala E, et al. Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer. *Int J Gynecol Cancer.* 2014;24(6):1010-1014.
84. Gershenson DM, Bodurka DC, Coleman RL, et al. Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum. *J Clin Oncol.* 2017;35(10):1103-1111.
85. Konstantinopoulos PA, Ceccaldi R, Shapiro GI, et al. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. *Cancer Discov.* 2015;5(11):1137-1154.
86. Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. *N Engl J Med.* 2018;379(26):2495-2505.
87. Monk BJ, Parkinson C, Lim MC, et al. A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). *J Clin Oncol.* 2022;40(34):3952-3964.
88. Scher KS, Hurria A. Under-representation of older adults in cancer registration trials: known problem, little progress. *J Clin Oncol.* 2012;30(17):2036-2038.
89. Jorgensen TL, Teiblum S, Paludan M, et al. Significance of age and comorbidity on treatment modality, treatment adherence, and prognosis in elderly ovarian cancer patients. *Gynecol Oncol.* 2012;127(2):367-374.
90. Wildiers H, Heeren P, Puts M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. *J Clin Oncol.* 2014;32(24):2595-2603.
91. Falandry C, Pommeret F, Gladiéff L, et al. Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study. *Lancet Healthy Longev.* 2022;3(3):e176-e185.
92. Thrall MM, Goff BA, Symons RG, et al. Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly. *Obstet Gynecol.* 2011;118(3):537-547.
93. Moore KN, Reid MS, Fong DN, et al. Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply? *Gynecol Oncol.* 2008;110(2):133-139.
94. Wright JD, Herzog TJ, Neugut AI, et al. Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced-stage ovarian cancer. *Obstet Gynecol.* 2012;120(4):871-881.
95. Coleman RL, Spirtos NM, Enserro D, et al. Secondary surgical cytoreduction for recurrent ovarian cancer. *N Engl J Med.* 2019;381(20):1929-1939.
96. Shi T, Zhu J, Feng Y, et al. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol.* 2021;22(4):439-449.
97. Harter P, Sehouli J, Vergote I, et al. Randomized trial of cytoreductive surgery for relapsed ovarian cancer. *N Engl J Med.* 2021;385(23):2123-2131.
98. Fotopoulou C, Zang R, Gultekin M, et al. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation. *Ann Surg Oncol.* 2013;20(4):1348-1354.
99. Armbrust R, Chekerov R, Sander S, et al. Surgery due to mechanical bowel obstruction in relapsed ovarian cancer: clinical and surgical results of a bicentric analysis of 87 patients. *Arch Gynecol Obstet.* 2022;305(4):963-968.